LASA SUPERGENERICS LIMITED

LASA SUPERGENERICS LIMITED

Corporate Office : B/207, "CITI POINT", Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59
Tel : +91 22 4970 1092 • Email : info@lasalabs.com • Website : www.lasalabs.com

Ref. No.: LASA/SE/18-19/039

Wednesday November 14, 2018

To, Corporate Services Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department **National Stock Exchange of India Limited** "Exchange Plaza", Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA

Dear Sir/Madam,

Sub. : Outcome of Board Meeting held today i.e 14.11.2018

Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company have approved the Statement of Unaudited Financial Results for the quarter and half year ended September 30, 2018.

A copy of the statement of Unaudited Financial Results along with Limited Review Report submitted by the Statutory Auditors of the Company are attached herewith.

The Board meeting of the Company commenced today at 1.00 p.m. and concluded with a vote of thanks to the Chair at 4.00 p.m.

The above information is also available on the company's website at www.lasalabs.com and on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

Please take the same on your records.

Thanking You
For Lasa Supergenerics Limited

LASA SUPERGENERICS LTD.

Nidhi Kulshreshtha
Company Secretary and Compliance Officer
Encl: as above

V. K. Thanawala
B.COM., F.C.A

thanawala & co.
CHARTERED ACCOUNTANTS

INDEPENDENT AUDITORS LIMITED REVIEW REPORT

To,
THE BOARD OF DIRECTORS,
LASA SUPERGENERICS LIMITED
MUMBAI

We have reviewed the accompanying statement of Unaudited Financial Results of **M/s.Lasa Supergenerics Limited** ("the Company"),for the quarter and half year ended 30 September 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Read with SEBI circular number CIR/CFD/FAC/62/2016 dated 05 July 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410. Review of Interim Financial Information Performed by the Independent Auditor of the Entity,' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with rules issued there under and other recognized accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of ,Regulation 33 of the SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 read with SEBI circular number CIR/CFD/FAC/62/2016 dated 05 July 2016 including the manner in which it is to be disclosed, or that contains any material misstatement.

For Thanawala & company
Chartered Accountants
Firm Reg. No.: 110948W

THANAWALA & CO. MUMBAI M.No.15632 Firm Reg. No. 110948W CHARTERED ACCOUNTANTS

CA Vijay K Thanawala
Proprietor
Membership No. 015632
Mumbai, 14th November, 2018

505,abhay steel house, 5th floor , 22 - baroda street, iron market ,Mumbai - 400 009.
tel.no.: 2348 6679 / 2348 4336 / 6631 8590 / 6631 8591

LASA SUPERGENERICS LIMITED

LASA SUPERGENERICS LIMITED

Corporate Office : B/207, "CITI POINT", Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59
Tel : +91 22 4970 1092 • Email : info@lasalabs.com • Website : www.lasalabs.com

Statement of Unaudited Financial Results for the Quarter ended 30th September, 2018

(Rs. In Lakhs)

Particulars	Quarter ended			Half Year Ended		Year ended
	30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
1. INCOME						
a. Revenue from Operations	4,074.48	3,292.06	6,453.07	7,366.54	12,554.09	24,583.88
b. Other Income	103.98	101.88	135.21	205.86	265.08	348.66
Total Income	**4,178.45**	**3,393.94**	**6,588.28**	**7,572.40**	**12,819.17**	**24,932.54**
2. Expenses						
a. Cost of Materials consumed	1,784.48	1,701.13	5,209.43	3,485.61	8,365.17	17,205.86
b. Cost of Traded Goods	1,174.13	599.79		1,773.91		-
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	41.35	(184.29)	(938.45)	(142.93)	(403.11)	(55.34)
d. Excise Duty on Sales (Refer Note No.2)	-	-	-	-	231.29	231.29
e. Employee benefits expenses	285.93	268.21	256.82	554.14	494.29	1,027.09
f. Finance costs (Refer Note No.3)	397.72	360.96	242.19	758.68	495.57	1,134.35
g. Depreciation & amortizations expenses	485.07	480.13	609.11	965.21	850.63	1,816.66
h. Other Expenses	443.80	385.65	621.65	829.44	1,032.09	2,049.30
Total Expenses (a to g)	**4,612.48**	**3,611.58**	**6,000.75**	**8,224.06**	**11,065.94**	**23,409.21**
Exceptional Items			-	-	-	-
3. Profit / (Loss) before tax (1-2)	**(434.03)**	**(217.64)**	**587.54**	**(651.67)**	**1,753.24**	**1,523.33**
4. Tax expense						
Current Tax	-	-	119.58	-	361.90	316.33
Deferred Tax	(307.10)	79.97	(398.42)	(227.13)	(180.30)	(26.99)
Short / Excess income tax provision for earlier years	70.69	-	-	70.69	1.73	-
5. Net Profit / (Loss) after tax (3-4)	**(197.61)**	**(297.61)**	**866.37**	**(495.22)**	**1,569.91**	**1,233.99**
6. Other Comprehensive Income						
Items that will not be reclassified into Profit or Loss						
- Remeasurement of Defined Benefit Plans (Net of tax)	(0.38)	-	(0.36)	(0.38)	(1.11)	(1.42)
7. Total Comprehensive Income for the year (after tax) (5+6)	**(197.99)**	**(297.61)**	**866.01**	**(495.60)**	**1,568.80**	**1,232.58**
8. Paid-up Equity Share Capital (Face Value of Re. 10 /- each)	2,286.44	2,286.44	2,286.44	2,286.44	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance Sheet	8,952.04	9,150.03	9,783.86	8,952.04	9,783.86	9,447.64
10. Earnings per Equity Share (of Rs. 10/- each)						
(a) Basic	(0.86)	(1.30)	3.79	(2.17)	6.87	5.40
(b) Diluted	(0.86)	(1.30)	3.79	(2.17)	6.87	5.40

See accompanying Notes to the Financial Results

LASA SUPERGENERICS LIMITED

LASA SUPERGENERICS LIMITED

Corporate Office : B/207, "CITI POINT", Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59
Tel : +91 22 4970 1092 • Email : info@lasalabs.com • Website : www.lasalabs.com

LASA SUPERGENERICS LIMITED
CIN: L24233MH2016PLC274202
Balance Sheet as at Sep 30, 2018

(Rs. In Lakhs)

Particulars	Note No.	As at 30.09.2018	As at 30.06.2018	As at 30.09.2017	As at 31 March 2018
ASSETS					
Non-current assets					
Property, Plant and Equipment	3	16,287.13	16,725.81	14,619.86	16,364.77
Capital Work in Progress	3	695.79	695.79	1,699.98	698.78
Intangible assets	3	602.54	599.39	517.47	599.38
Intangible assets under development	3	25.10	25.10	23.85	25.10
Financial Assets					
Non Current Investments	4	0.10	0.10	0.10	0.10
Loans	5	72.82	72.41	70.85	71.81
Other non-current assets	6	-	-	-	-
Deffered Tax Assets	17	60.68	-	-	-
		17,744.16	18,118.60	16,932.11	17,759.94
Current assets					
Inventories	7	3,902.24	3,994.93	3,851.25	4,223.45
Financial Assets					
Trade receivables	8	2,234.57	2,298.41	6,546.16	4,215.11
Cash and cash equivalents	9	86.14	205.50	94.31	49.69
Bank balances other than cash & cash equivalents	10	219.94	216.84	106.42	213.79
Loans	11	5.00	5.60	0.60	5.60
Other current assets	12	2,170.97	2,147.78	940.53	2,210.44
		8,618.86	8,869.07	11,539.28	10,918.09
		26,363.02	26,987.67	28,471.39	28,678.03
EQUITY AND LIABILITIES					
EQUITY					
Equity Share capital	13	2,286.44	2,286.44	2,286.44	2,286.44
Other Equity	14	8,952.04	9,150.03	9,783.86	9,447.64
		11,238.48	11,436.47	12,070.30	11,734.09
LIABILITIES					
Non-current liabilities					
Financial Liabilities					
Non Current Borrowings	15	6,547.15	6,417.04	4,591.84	6,026.99
Provisions	16	29.30	25.35	27.86	23.75
Deferred Tax Liabilities	17	-	246.55	14.03	166.58
		6,576.46	6,688.94	4,633.73	6,217.33
Current liabilities					
Financial Liabilities					
Current Borrowings	18	2,310.22	2,339.25	2,219.52	2,983.04
Trade payables	19	3,298.70	3,484.53	6,507.12	4,793.52
Other financial liabilities	20	1,700.80	1,882.50	2,146.64	1,711.89
Other current liabilities	21	568.69	711.37	231.79	815.33
Provisions	22	306.12	151.41	110.25	129.31
Current tax liabilities (net)	23	363.55	293.19	552.03	293.52
		8,548.08	8,862.25	11,767.35	10,726.61
		26,363.02	26,987.67	28,471.39	28,678.03

For Lasa Supergenerics Limited

Omkar Herlekar
(Chairman & Managing Director)
DIN: 01587154

Place : Mumbai
Date : 14th November,2018

LASA SUPERGENERICS LIMITED

LASA SUPERGENERICS LIMITED

Corporate Office : B/207, "CITI POINT", Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59
Tel : +91 22 4970 1092 • Email : info@lasalabs.com • Website : www.lasalabs.com

Notes :

1) The Above Financial Results were reviewed by the audit committee of the board on 14th November, 2018 and approved by the Board of Directors of the company at their meting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accoradance with Ind As notified under the companies (Accounting Standards) Rule 2015.

2) Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenue are disclosed net of GST. Revenues for the earlier periods included excise duty which is now subsumed in the GST effective from 1st July 2017. Accordingly, revenues for the six month ended 30th September, 2018 are not comparable with previous comparative quater ended 30th September, 2017.

3) Finance cost includes Rs. 122.93 Lakhs being loss on account of foreign exchange fluctuations and Rs. 54.38 Lakhs being gain on account of foreig exchange fluctuations during the quarter ended 30th September, 2018 and 30th September, 2017 resepctively.

4) The Company has only one reportable segment i.e. Active Pharmaceutical Ingredients (API)

5) The pricing pressure of most of the raw materials in reporting quaters continued to increase and rached at a such extent that in order to utilise full capacity we may have taken biggest hit either on margins or in business front. Margins would have negative if the case be of full capacity utilisation, however to maintain reasonable balance on margins we decided to execute business upto extent which shall give atleast positive level of gross margins. Also one of the major reasons for declined top lines in drastic drop in universal demand for one of our top product. We are putting all our efforts to improve profitability in upcoming quaters.

6) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

For Lasa Supergenerics Limited

Omkar Herlekar
Chairman & Managing Director
(DIN No. 01587154)

Place : Mumbai
Date : 14th November, 2018